Why Pfizer’s BRAFTOVI results could reshape first-line treatment for BRAF-mutant mCRC
Pfizer reports positive BREAKWATER data for BRAFTOVI in BRAF-mutant mCRC. Find out what this could change for frontline colorectal cancer care.
Pharma & Biotech